Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
17 mai 2022 16h05 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and...
Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
16 mai 2022 08h15 HE
|
Cellectis Inc.
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
05 mai 2022 18h12 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext & Nasdaq: CYAD), please note that in the...
Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
05 mai 2022 16h05 HE
|
Celyad Oncology SA
Enrollment continues in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM)Dialogue continues with...
Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN
28 avr. 2022 08h00 HE
|
Cellectis Inc.
Preclinical data demonstrates that UCART123 effectively eliminates AML with no major impact on normal hematopoietic progenitor cellsPreclinical data shows proof-of-principle that UCART123 cells have...
Bone Therapeutics obtient un financement de 5 M€
12 avr. 2022 01h00 HE
|
Bone Therapeutics SA
INFORMATION REGLEMENTEE NE PAS PUBLIER, DISTRIBUER OU DIFFUSER, EN TOUT OU EN PARTIE, DIRECTEMENT OU INDIRECTEMENT, AUX ETATS-UNIS, EN AUSTRALIE, AU CANADA, AU JAPON, EN AFRIQUE DU SUD OU DANS...
Bone Therapeutics Secures EUR 5 Million Financing
12 avr. 2022 01h00 HE
|
Bone Therapeutics SA
REGULATED INFORMATION NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER...
Bone Therapeutics réoriente sa stratégie autour du développement d’ALLOB, son produit de thérapie cellulaire phare
29 mars 2022 01h00 HE
|
Bone Therapeutics SA
INFORMATION RÉGLEMENTÉE Réorientation stratégique afin de concentrer les efforts de Bone Therapeutics sur l’obtention des principaux résultats de l’étude de Phase IIb évaluant ALLOB dans...
Bone Therapeutics to strategically focus on lead cell therapy product ALLOB
29 mars 2022 01h00 HE
|
Bone Therapeutics SA
REGULATED INFORMATION Strategic focus revised and fully focused on achieving topline results of the ALLOB Phase IIb study in tibial fractures. Discussions for ALLOB global partnership...
Monthly information on share capital and company voting rights
11 févr. 2022 16h30 HE
|
Cellectis Inc.
NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...